RESEARCH DOSSIER / EVIDENCE-LED RECORD
Research question, methods and contribution
Inhalable dexamethasone-loaded niosomes and proniosomes: chemistry, formulation, and aerosol performance.
The scientific question
A therapeutic carrier that works in a vial must also survive aerosolization and deliver a meaningful fraction of its contents to the intended pulmonary region.
Approach and methods
Formulation design, surfactant/cholesterol calculations and a planned integrated analytical workflow involving chromatographic assay development, DLS, nebulization and NGI deposition assessment.
PROJECT STATUS / OCTOBER 2026
What is documented, and what remains to be demonstrated
Documented development work. Surfactant/cholesterol preformulation calculations and a Python niosome-design tool are part of my current thesis-related work. A calculation or working software tool is not experimental evidence of drug encapsulation or inhalation performance.
Investigation in progress. My current work covers formulation preparation, physicochemical characterization and nebulization behaviour. I will report quantitative batch, particle-size and drug-assay results with the corresponding experimental methods once those measurements are ready for public release.
Analytical endpoints to establish. Chromatographic drug assay, DLS characterization, before-and-after-nebulization comparison and NGI aerodynamic-deposition analysis require measured data, method conditions, controls and uncertainty reporting before any outcome claim can be made. Planned and unpublished endpoints are not shown as results.
Work still being analysed remains part of the thesis record and is not represented here as a completed result.
MEASUREMENT / INTERPRETATION
How the evidence is read
Particle properties, drug assay and aerosol deposition
The planned analytical endpoints include DLS measurements of dispersed vesicle size and polydispersity, chromatographic drug assay, and post-nebulization evaluation. NGI testing would characterize aerodynamic deposition under specified in vitro device conditions, if and when those measurements are obtained.
DLS particle size is not aerodynamic deposition, and in vitro NGI deposition is not clinical delivery or efficacy. Encapsulation efficiency, post-nebulization stability and pulmonary performance are not established findings for this ongoing thesis; these remain planned or unverified endpoints.
My documented contribution
As part of my MSc thesis, my work includes experimental formulation planning and preparation, physicochemical testing workflows, research analysis and thesis writing. I developed formulation calculations and a Python niosome-design tool. The formulation and testing workflow remains in progress; this is not a claim of completed experimental results or a published manuscript.
Evidence, status and limitations
Ongoing project. No aerosol deposition, encapsulation efficiencies, clinical performance, or unpublished thesis outcomes are claimed.
Concept schematic, not experimental MSc data.